Glycophos

Glycophos is a prescription injectable solution that contains sodium glycerophosphate pentahydrate as its active ingredient. Delivered as an intravenous preparation, this phosphate supplement provides inorganic phosphate for cellular metabolism and ATP synthesis. It is marketed in the European Union and is used under medical supervision for electrolyte replenishment, particularly when oral phosphate intake is insufficient. The product is supplied in sterile vials and requires aseptic handling by qualified healthcare professionals.

Glycophos is indicated for clinical situations that require rapid phosphate repletion via the intravenous route.

- Treatment of hypophosphatemia associated with critical illness, surgery, or prolonged fasting. - Phosphate replacement in patients receiving total parenteral nutrition (TPN). - Support of bone mineralization in patients with chronic phosphate deficiency. - Adjunct therapy during renal replacement procedures where phosphate loss is anticipated. - Management of electrolyte disturbances in intensive care settings. - Correction of phosphate deficits prior to high‑dose chemotherapy regimens that may deplete phosphate stores.

Intravenous administration of Glycophos may be associated with a range of adverse reactions, most of which are mild and transient.

Common: - Transient infusion site pain or erythema. - Mild nausea or vomiting. - Temporary elevation of serum calcium. - Low‑grade fever. - Headache. - Dizziness. - Transient hypotension.

Serious: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation. - Acute respiratory distress syndrome (ARDS) related to fluid overload. - Anaphylactic or severe hypersensitivity reactions. - Cardiac arrhythmias associated with electrolyte shifts. - Renal dysfunction due to phosphate nephrocalcinosis.

Because Glycophos delivers a concentrated phosphate load directly into the bloodstream, several precautions should be observed before and during therapy.

- Verify baseline serum phosphate, calcium, and renal function prior to infusion. - Adjust dose in patients with renal insufficiency or on dialysis. - Monitor serum electrolytes (phosphate, calcium, magnesium) during and after administration. - Avoid rapid infusion rates that may precipitate calcium‑phosphate complexes. - Use caution in patients with a history of hypersensitivity to phosphate preparations. - Consider fluid balance in individuals at risk for volume overload. - Do not administer concurrently with calcium‑containing solutions in the same line.

Glycophos can interact with other medications or solutions that affect electrolyte balance or calcium metabolism, requiring careful coordination.

Avoid: - Simultaneous intravenous calcium gluconate or calcium chloride infusions, which may cause insoluble calcium‑phosphate precipitation. - High‑dose vitamin D analogues that increase intestinal calcium absorption, raising risk of hypercalcemia. - Loop diuretics that promote calcium loss, potentially worsening electrolyte shifts.

Use with caution: - Anticoagulants such as heparin, as phosphate may alter clotting parameters. - Certain antibiotics (e.g., aminoglycosides) that are nephrotoxic, especially in patients with renal impairment. - Chemotherapeutic agents that can cause tumor lysis syndrome, increasing phosphate release.